AbCellera Biologics (ABCL) Invested Capital: 2020-2025
Historic Invested Capital for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $964.0 million.
- AbCellera Biologics' Invested Capital fell 12.23% to $964.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $964.0 million, marking a year-over-year decrease of 12.23%. This contributed to the annual value of $1.1 billion for FY2024, which is 11.53% down from last year.
- Latest data reveals that AbCellera Biologics reported Invested Capital of $964.0 million as of Q3 2025, which was down 4.27% from $1.0 billion recorded in Q2 2025.
- Over the past 5 years, AbCellera Biologics' Invested Capital peaked at $1.3 billion during Q3 2022, and registered a low of $964.0 million during Q3 2025.
- Moreover, its 3-year median value for Invested Capital was $1.1 billion (2024), whereas its average is $1.1 billion.
- Its Invested Capital has fluctuated over the past 5 years, first spiked by 32.85% in 2022, then decreased by 12.66% in 2025.
- Quarterly analysis of 5 years shows AbCellera Biologics' Invested Capital stood at $1.0 billion in 2021, then rose by 21.82% to $1.3 billion in 2022, then fell by 5.85% to $1.2 billion in 2023, then fell by 11.53% to $1.1 billion in 2024, then decreased by 12.23% to $964.0 million in 2025.
- Its Invested Capital was $964.0 million in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.0 billion in Q1 2025.